honeypot link

MSD Manual

Please confirm that you are a health care professional

Gastrointestinal Stromal Tumors (GISTs)


Minhhuyen Nguyen

, MD, Fox Chase Cancer Center, Temple University

Last full review/revision Jun 2019| Content last modified Jun 2019
Click here for Patient Education

Gastrointestinal stromal tumors (GISTs) are tumors of the gastrointestinal tract derived from mesenchymal precursor cells in the gut wall. They result from mutations of a growth factor receptor gene, C-KIT. Some are caused by previous radiation therapy to the abdomen for other tumors.

Tumors are slow growing, and malignant potential varies from minimal to significant. Most (60 to 70%) occur in the stomach, 20 to 25% in the small bowel, and a small number in the esophagus, colon, and rectum. Average age at presentation is 50 to 60.

Symptoms of GISTs vary with location but include bleeding, dyspepsia, and obstruction.

Diagnosis of GISTs is usually by endoscopy, with biopsy and endoscopic ultrasonography for staging.

Treatment of GISTs is surgical removal. The tyrosine kinase inhibitor imatinib can be used when tumors are positive for the KIT protein CD117; it is effective for patients with unresectable and/or metastatic malignant GISTs and also as adjuvant treatment following resection in adults (1).

Treatment reference

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest


iOS Android
iOS Android
iOS Android